Clinical trial · no report yet · Phase 3
NCT04459715
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- NCT04459715 ↗
- Terminated
- EMD Serono Research & Development Institute, Inc.
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 6 | |
| Podcasts | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Xevinapant (Debio 1143); Cisplatin; Intensity Modulation Radiation Therapy (IMRT); Placebo
- Arms
- Xevinapant (Debio 1143) · Experimental
- Placebo · Active comparator
- Enrollment
- 730
- Primary outcomes
- Event-Free Survival (EFS) as Assessed by Blinded Independent Review Committee (BIRC)
- Sponsor
- EMD Serono Research & Development Institute, Inc. with GORTEC (Head and Neck Oncology and Radiotherapy Group), Merck KGaA, Darmstadt, Germany
- Start
- Aug 7, 2020
- Primary completion
- Sep 18, 2024
- Results posted
- Yes
- Registry record
- NCT04459715 · updated Oct 8, 2025
Publications
linked from the registry- Bourhis J, Licitra LF, Burtness B, Psyrri A, Haddad R, Harrington K, Cohen EEW, Tao Y, Tiscoski KA, Matitashvili A, Tahara M, Sukari A, Rutkowski T, Salas S, Nauwelaerts H, Scheerlinck R, Ha NT, Schroeder A, Rodriguez-Gutierrez A, Schoenfeld JD. Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. J Clin Oncol. 2025 Oct 10;43(29):3209-3220. doi: 10.1200/JCO-25-00272. Epub 2025 Sep 3. PubMed 40902136
- Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May;18(14):1669-1678. doi: 10.2217/fon-2021-1634. Epub 2022 Feb 17. PubMed 35172587